Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Geb Impact Technology is a Hong Kong-based biotechnology company specializing in the sustainable cultivation of microalgae to produce high-value bioactive ingredients. The company utilizes proprietary fermentation and bioreactor technologies to manufacture premium products such as astaxanthin, docosahexaenoic acid (DHA), and protein-rich algal biomass. Their offerings target the nutraceutical, cosmeceutical, and functional food industries, focusing on high purity and environmental sustainability. By optimizing metabolic pathways in specific algae strains, Geb Impact provides scalable solutions for global health and nutrition needs. The company's platform integrates advanced bioprocessing with strain selection to ensure consistent quality and yield of natural compounds. Geb Impact is recognized for its contribution to the alternative protein sector and its commitment to reducing the environmental footprint of ingredient production.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Geb Impact Technology.